Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
Pilot Study of Cabazitaxel and Paclitaxel in HER2 Negative Breast Cancer

90 patients with HER2 negative breast cancer will be randomised to receive 18 weeks of chemotherapy treatment, either 6 cycles of 3 weekly Cabazitaxel or 6 cycles of weekly Paclitaxel to

  • 263 views
  • 23 Jan, 2021
  • 12 locations
A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis

Current agents administered in therapeutic regimens of prostate cancer employ different mechanisms to eliminate neoplastic cells by inducing substantial apoptosis and causing tumor regression. Treatment with neoadjuvant chemotherapy before radical prostatectomy may better control the tumor before it has the chance to convert into the disease of castration-resistant prostate cancer …

  • 5 views
  • 14 May, 2022
  • 2 locations
XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

This Phase 2 study will investigate the safety and clinical activity of XmAb20717 alone or in combination with standard of care anticancer therapies in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been treated with at least 2 prior lines of anticancer therapy.

  • 0 views
  • 07 Jun, 2022
  • 10 locations
ProBio: An Outcome-adaptive and Randomized Multi-arm Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC) (ProBio)

Metastatic castrate resistant prostate cancer (mCRPC) is an advanced form of prostate cancer and it is estimated that around 20-30% of all prostate cancer diagnoses will develop mCRPC at some point in their disease trajectory. The last years, new drugs have been approved for treatment of mCRPC. Although the drugs …

  • 2 views
  • 23 Sep, 2022
  • 24 locations
Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (CABPOSTAAT)

is a Phase II Study of Cabazitaxel plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC). The current study is designed to determine if cabazitaxel will improve

castration-resistant prostate cancer
enzalutamide
androgen ablation
adenocarcinoma of prostate
metastasis
  • 4 views
  • 08 Feb, 2022
  • 1 location
CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

treatment combination. This study will evaluate dose levels of carboplatin AUC 4 with cabazitaxel 20 mg/m2. Patients will be treated with the combination of ADT and carboplatin and cabazitaxel for 6 cycles

gonadorelin
abiraterone
cabazitaxel
neutrophil count
luteinizing hormone-releasing hormone agonist
  • 18 views
  • 30 Apr, 2022
  • 8 locations
Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer

cancer. Cabazitaxel may overcome resistance to docetaxel and paclitaxel and might have clinical activity in patients with metastatic and progressive germ cell tumors.

salvage treatment
high dose chemotherapy
germ cell tumor
docetaxel
germ cell cancer
  • 0 views
  • 04 Oct, 2022
  • 2 locations
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (LuCAB)

This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.

  • 0 views
  • 04 Oct, 2022
  • 1 location
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder (CGC)

The investigators intend to evaluate the safety and toxicity profile of intravesically administered multidrug regimen of Cabazitaxel, Cisplatin and Gemcitabine in treatment refractory

cancer
cabazitaxel
bcg vaccine
radical cystectomy
mitomycin
  • 17 views
  • 24 Mar, 2022
  • 1 location
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

This phase II trial studies the effect of cabazitaxel, carboplatin, and cetrelimab followed by niraparib with or without cetrelimab in treating patients with aggressive variant prostate cancer

  • 0 views
  • 11 Mar, 2022
  • 1 location